MO MO Altria Group, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Own MO for regulatory moat and dividends

Altria resilient earnings offset declining cigarette volumes

Seeking Alpha highlights Goldman Sachs' bullish price targets on Altria and Philip Morris.

Author argues healthcare and staples outperform in recessions and says he adds them alongside.

Altria raised the low end of FY2026 EPS guidance after a strong first half, signaling confidence in pricing power, smoke-free portfolio momentum, and moderating cigarette industry declines despite consumer pressure.

Premarket movers report shows mixed earnings reactions with Meta sliding 8% on disappointing.

PM and MO NTM PE multiples cited as near the top of their recent historical ranges.

Barbarian Capital notes Philip Morris hitting a new intraday all-time high and questions.

Summarizes FDA guidance on vapes and pouches; no directional view from speaker.

Dr. Friedrich Franz tweets a WSJ report that Trump is pressuring the FDA to approve flavored.

Altria delivered a strong Q1 and shifted expected 2026 EPS growth to be more balanced between first and second half, but kept full-year guidance unchanged given macro uncertainty, gas prices, and consumer trade-down pressure.

Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27.

PMI estimated ~25 million cans of surplus Zyn inventory in the US supply chain at end-2025, which largely normalized in Q1 2026, explaining why Q1 shipments were below consumer offtake. — Investors tracking US nicotine pouch volumes need to adjust for this inventory swing; it also suggests competitors may face similar channel dynamics.

"Zyn... is by far the biggest winner in the roughly 20 billion dollars oral tobacco market." While the video focuses on PMI's success, this implies a direct threat to competitors. Altria (MO) and British American Tobacco (BTI) have competing products (on! and Velo/Vuse), but Zyn is described as the "superior product" with dominant brand equity ("Zyn is not a sin"). If PMI is winning the growth war in oral nicotine, legacy competitors are at risk of losing the only growing segment of the industry. Watch these tickers for market share erosion. If Zyn continues to dominate the US market via the new Colorado facility, MO and BTI face an existential growth crisis. Competitors could slash prices to defend market share, triggering a margin-crushing price war.

Author is short MO as a bearish bet against declining traditional cigarette volumes relative.

Bondi and Rep. Fry discuss the infiltration of "illegal Chinese vapes" laced with drugs and the administration's partnership with HHS to crack down on these illicit imports. The disposable vape market has been flooded with non-compliant Chinese imports that undercut regulated players. A federal crackdown clears the market for authorized, compliant manufacturers (Big Tobacco's vape arms). Reduced illicit competition boosts pricing power and market share for established tobacco companies with FDA-authorized vapor products. Enforcement may be porous; consumers may shift to the black market rather than compliant products.

The 2026 guidance of 2.5% to 5.5% EPS growth reflects a balanced but cautious outlook, with growth weighted to the second half due to investments in import/export capabilities and limited impact from enforcement on illicit vapor.